Search Results
Apr 15, 2026, 02:58 ET Sectra completes Oxipit acquisition, accelerating autonomous AI in radiology
https://news.cision.com/sectra/i/radiologist-reading-lung-x-ray-in-sectra-s-solution,c3528404Radiologist reading lung X-ray in Sectra's solution
More news about: Sectra
Apr 14, 2026, 17:45 ET Partner Therapeutics announces submission of supplemental Biologics License Application (sBLA) to FDA for BIZENGRI® (zenocutuzumab-zbco) in NRG1 Fusion Positive Cholangiocarcinoma and Inclusion in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis reactions.Interstitial Lung Disease/PneumonitisBIZENGRI can cause serious and life-threatening interstitial lung disease (ILD)/pneumonitis.In the eNRGy study, ILD/pneumonitis occurred in 2 (1.1%) patients
More news about: Partner Therapeutics, Inc.
Apr 14, 2026, 15:36 ET ACR Foundation and Author Shira Boehler Launch Cancer Doesn't Care Fund to Accelerate Early Detection Nationwide
many people are diagnosed with lung cancer at late stages, where survival is limited, because U.S. Preventive Services Task Force rules focus mainly on age and smoking history," said Kim Sandler, MD, co-chair of the ACR Lung Cancer Screening Committee. "Many who develop lung cancer have never smoked or
More news about: American College of Radiology
Apr 14, 2026, 14:25 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 14, 2026, 10:17 ET CSF Liquid Biopsy May Help Clarify Inconclusive Leptomeningeal Disease Cases, Study Finds
time.Key FindingsThe study analyzed 118 CSF specimens from patients with a provisional diagnosis of metastatic CNS cancer, spanning breast, lung, and other primary malignancies. Summit™ identified clinically significant variants in all 118 specimens across 22 of the 32 genes on the panel, including
More news about: Belay Diagnostics
Apr 14, 2026, 09:30 ET Lung Cancer Research Foundation Grants Team Science Award Focused on Curing EGFR-Mutant Lung Cancers
Project 2. Rounding out the investigative team are Deborah Markow, lung cancer patient advocate, and Kristen Labbe, MPH, as project coordinator.Lung cancer is the leading cause of cancer death worldwide. A common subtype, lung adenocarcinoma (LUAD), frequently carries mutations in the epidermal
More news about: Lung Cancer Research Foundation
Apr 14, 2026, 08:46 ET Sarasota Memorial Cancer Team Achieves 75% Early-Stage Lung Cancer Diagnosis Rate by Expanding Detection Beyond Screening
"Diagnosing lung cancer early is the single, most important thing we can do to save lives," said Joseph Seaman, MD, associate chief medical officer at Sarasota Memorial and a pulmonologist who helped develop SMH's early detection program. "When detected early, in Stage I or II, 70% of lung cancer patients
More news about: Sarasota Memorial Health Care System
Apr 14, 2026, 06:00 ET Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
broad range of solid tumors, including head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer; 2) ADCE-D01 targeting uPARAP, which is overexpressed in high unmet need cancers, including soft tissue sarcoma and other cancers of mesenchymal
More news about: Adcendo
Apr 14, 2026, 06:00 ET Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
broad range of solid tumors, including head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer; 2) ADCE-D01 targeting uPARAP, which is overexpressed in high unmet need cancers, including soft tissue sarcoma and other cancers of mesenchymal
More news about: Adcendo
Apr 13, 2026, 20:00 ET Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO
has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing Phase III global clinical
More news about: Kelun-Biotech
Apr 13, 2026, 09:00 ET New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
310.600.6746 [i] STORM-PE was not powered to detect differences in safety [ii] "Learn about Pulmonary Embolism," American Lung Association. Accessed on Oct. 7, 2025.
More news about: Penumbra, Inc.
Apr 12, 2026, 07:15 ET AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026
treatment with ELAHERE, including blurred vision, dry eyes, sensitivity to light, eye pain, eye redness, or new or worsening vision changes.Lung problems (pneumonitis). ELAHERE can cause severe or life-threatening inflammation of the lungs that may lead to death. Tell your healthcare provider
More news about: AbbVie
Apr 10, 2026, 18:24 ET Parnall Law Obtains $1.5 Million Settlement in New Mexico Drunk Driving Collision Case
the crash proved catastrophic for one of the firm's clients, causing her to suffer a traumatic brain injury (TBI), multiple rib fractures, bilateral lung injuries, and a subarachnoid hemorrhage, requiring immediate hospitalization and intensive care. Her treatment extended from emergency intervention
More news about: Parnall Law
Apr 10, 2026, 13:42 ET NAPT 2026 National Proton Conference Underscores Rapid Advances in Proton Therapy and Expanding Access Nationwide
(PCG) President of the Board of Directors and Chair of the PCG Lung Committee. Clinical highlights:Proton therapy is effective across thoracic malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer, malignant pleural mesothelioma, thymic malignancies,
More news about: The National Association for Proton Therapy
Apr 09, 2026, 21:00 ET ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406
ArkBioArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through
More news about: Arkbio
Apr 09, 2026, 21:00 ET ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406
ArkBioArkBio is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory/lung and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated R&D pipeline through
More news about: Arkbio
Apr 09, 2026, 20:00 ET Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer
and potentially transformational for COPD patients.Alongside her industry career, Maria has held a professorship at the National Heart & Lung Institute, Imperial College London — a position she continues to hold today. During her time leading the Imperial research group, she trained more than
More news about: Ailux
Apr 09, 2026, 18:01 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 09, 2026, 10:29 ET Cycle for Clean Air and Healthy Lungs: American Lung Association to Host Five Iconic Bike Treks in 2026
Learn more about all of the American Lung Association cycling events here.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and
More news about: American Lung Association
Apr 09, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
Apr 09, 2026, 09:05 ET Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Apr 09, 2026, 08:00 ET Deck Bio Launches Multi-Target T Cell Engager Platform for Solid Tumors, With Preclinical Data to be Presented at AACR 2026
beyond.The company's lead program, DBXO-1, is a multi-target T cell engager being developed for solid tumor indications, including non-small cell lung cancer and gastroesophageal cancer. Additional details will be highlighted during the upcoming presentation at the AACR Annual Meeting 2026.Conference
More news about: Deck Bio, Inc.
Apr 09, 2026, 07:16 ET Coreline Soft Aligns with Germany's New Lung Cancer Screening Reimbursement Framework from 2026, New Operational Requirements Introduced for Hospitals and Screening Programs
Germany's lung cancer screening project HANSE, where a single CT scan enables simultaneous analysis of lung cancer, cardiovascular disease, and emphysema.The company's solutions are already in use at leading
More news about: Coreline Soft
Apr 09, 2026, 07:00 ET AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension
evaluate the safety, tolerability, and efficacy of ROC-101 to treat patients with pulmonary arterial hypertension (PAH) or PH associated with interstitial lung disease (ILD-PH).
More news about: AllRock Bio
Apr 09, 2026, 07:00 ET OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
Treg depletion candidate targeting CTLA-4, in multiple solid tumor indications, including an ongoing pivotal clinical trial in squamous non-small cell lung cancer.More information: www.oncoc4.com.CONTACTSMedia RelationsPan
More news about: OncoC4